-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On September 7, Servier and Neurochlore announced that in two phase III clinical studies evaluating bumetanide and placebo in the treatment of autism spectrum disorder (ASD) in children and adolescents, no difference in efficacy was observed
Autism, also known as autism, is a disorder of mental development that occurs in infants and young children.
Bumetanide is a powerful diuretic that works by inhibiting the sodium-potassium-chloride cotransporter (NKCC1)
These two randomized, double-blind, placebo-controlled Phase III clinical trials were launched 4 years ago and were carried out in 14 countries (including 11 European countries)
Previously, the Ib trial of bumetanide in the treatment of autism was carried out by Neurochlore, which included 90 subjects in 6 centers in France